Recent Updates
Recently added Catalysts
CHE Positive Sentiment Score: 70/100

Michael D. Witzeman (513) 762- 6714  Chemed Reports First-Quarter 2025 Results   CINCINNATI

Key Takeaway: Chemed Corporation reported strong first-quarter results for 2025, with VITAS segment revenues increasing by 15.1% year-over-year. The company attributed $11.5 million to $12.5 million in revenue to the recent acquisition of Covenant Health's hospice assets. Roto-Rooter, while generating overall increased revenue, faced challenges with declines in certain service areas. The company maintains a robust cash position with no debt and plans to provide updated earnings guidance later in the year.

Market Sentiment Analysis

POSITIVE FACTORS

  • VITAS segment experienced a 15.1% revenue increase compared to the prior-year period.
  • Roto-Rooter branch commercial revenue increased by 7.3%, indicating strong performance in certain areas.
  • Chemed reported a healthy cash position with $173.9 million in cash and no debt.

CONCERNS & RISKS

  • Covenant Health's operations integration complicates revenue tracking and attribution.
  • Roto-Rooter saw a decline in independent contractor revenue by 6.4% compared to the prior year.
  • Adjusted EBITDA for Roto-Rooter decreased by 2.4%, indicating potential operational challenges.

Full Press Release Details

CONTACT: Michael D. Witzeman
Chemed Reports First-Quarter 2025 Results
CINCINNATI, April 23, 2025 Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its first quarter ended March 31, 2025, versus the comparable prior-year period.
Results for Quarter Ended March 31, 2025
Consolidated operating results:
VITAS segment operating results:
Roto-Rooter segment operating results:
As previously announced, VITAS completed its acquisition of the hospice assets and an assisted living facility of Covenant Health and Community Services, Inc. (Covenant Health) on April 17, 2024 for $85.0 million in cash. Before presenting VITAS' overall results, it is important to disclose
the methodology used in determining the impact of Covenant Health's acquisition on VITAS' overall results. VITAS had significant operations in two of the three Florida locations we acquired from Covenant Health. Those locations require that we estimate the Covenant Health impact, as once the operations are integrated, there are not separate results. For instance, there are no VITAS-specific referral sources versus Covenant Health-specific referral sources in these locations. It is very likely that referral sources in the area have historically referred to both VITAS and Covenant Health. We have used historical operating trends in these locations to determine what is legacy VITAS activity. All activity above those historical operating trends have been attributed as the Covenant Health impact. We have included the specifically determined impact as it relates to new operating territories acquired. Based on the above, we discuss the range of impact that Covenant had on the overall VITAS operating metrics.
Covenant Health contributed approximately $11.5 million to $12.5 million of revenue in the first quarter of 2025. This revenue translated to net income of approximately $1.8 million to $2.0 million. Adjusted EBITDA in the quarter attributed to Covenant Health is between $2.5 million and $2.7 million.
VITAS net revenue was $407.4 million in the first quarter of 2025, which is an increase of 15.1% when compared to the prior-year period. This revenue increase is comprised primarily of a 11.9% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 3.2%. Acuity mix shift negatively impacted revenue growth 112-basis points in the quarter when compared to the prior-year period's revenue and level-of-care mix. The combination of Medicare Cap and other contra revenue changes increased revenue growth by approximately 112-basis points.
In the first quarter of 2025, VITAS accrued $2.3 million in Medicare Cap billing limitation, essentially flat with the first quarter of 2024.
Of VITAS' 34 Medicare provider numbers, 24 provider numbers have a trailing 12-month Medicare Cap cushion of 10% or greater, four provider numbers have a cushion between 0% and 10%, and six provider numbers have a trailing 12-month Medicare Cap billing limitation totaling $19.6 million.
Average revenue per patient per day in the first quarter of 2025 was $207.58 which is 221-basis points above the prior-year period. Reimbursement for routine home care and high acuity care averaged $183.06 and $1,121.07, respectively. During the quarter, high acuity days-of-care were 2.6% of total days of care, a decline of 22-basis points when compared to the prior-year quarter.
The first quarter 2025 gross margin, excluding Medicare Cap, was 23.7% which is essentially flat with the same period of 2024. Selling, general and administrative expenses were $26.5 million in the first quarter of 2025 compared to $23.8 million in the prior-year quarter.
Adjusted EBITDA, excluding Medicare Cap, totaled $70.3 million in the quarter, an increase of 15.9% when compared to the prior year period. Adjusted EBITDA margin in the quarter, excluding Medicare Cap, was 17.2%.
Roto-Rooter generated quarterly revenue of $239.5 million in the first quarter of 2025, an increase of 1.8%, when compared to the prior-year quarter.
Roto-Rooter branch commercial revenue in the quarter totaled $57.7 million, an increase of 7.3% from the prior-year period. This aggregate commercial revenue change consisted of plumbing declining 4.3%, excavation increasing 38.0%, and water restoration increasing 14.0%. Commercial drain cleaning revenue was essentially flat between quarters.
Roto-Rooter branch residential revenue in the quarter totaled $167.2 million, an increase of 1.7%, over the prior-year period. This aggregate residential revenue change consisted of drain cleaning declining 5.5%, plumbing declining 4.2%, excavation increasing 3.0%, and water restoration increasing 12.5%.
In the first quarter of 2025, revenue from independent contractors declined 6.4% as compared to the same period of 2024.
Roto-Rooter's first quarter 2025 gross margin was 50.9%. This compares to the prior year quarter's gross margin of 51.9%. Roto-Rooter's selling, general and administrative expenses were $62.6 million in the quarter, which is an increase of 2.3% compared to the first quarter of 2024.
Adjusted EBITDA in the first quarter of 2025 totaled $59.2 million, a decrease of 2.4% when compared to the first quarter of 2024. The Adjusted EBITDA margin in the quarter was 24.7% which represents a 108-basis point decline from the first quarter of 2024.
As of March 31, 2025, Chemed had total cash and cash equivalents of $173.9 million and no current or long-term debt.
In June 2022, Chemed entered into a five-year $550 million Amended and Restated Credit Agreement (Credit Agreement). This Credit Agreement consisted of a $100 million amortizable term loan and a $450 million revolving credit facility. The interest rate on this Credit Agreement has a floating rate that is currently SOFR plus 100-basis points. There is approximately $404.5 million of undrawn borrowing capacity under the Credit Agreement after excluding $45.5 million for Letters of Credit.
During the quarter, the Company repurchased 50,000 shares of Chemed stock for $29.8 million which equates to a cost per share of $595.15. As of March 31, 2025, there was approximately $225.6 million of remaining share repurchase authorization under its plan.
Management anticipates providing updated 2025 earnings guidance as part of the June 30, 2025 earnings press release.
As previously disclosed, Chemed will host a conference call and webcast at 10 a.m., ET, on Thursday April 24, 2025, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through the investor relations section of Chemed's website, Investor Relations Home | Chemed Corporation or the hosting website https://edge.media-server.com/mmc/p/ey8mpmti.
Participants may also register via teleconference at:
Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time.
A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. You may access the replay via webcast through the investor relations section of Chemed's website.
Chemed operates in the healthcare field through its VITAS Healthcare Corporation subsidiary. VITAS provides daily hospice services to patients with severe, life-limiting illnesses. This type of care is focused on making the terminally ill patient's final days as comfortable and pain-free as possible.
Chemed operates in the residential and commercial plumbing and drain cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides plumbing, drain cleaning, and water cleanup services through company-owned branches, independent contractors and franchisees in the United States and Canada. Roto-Rooter also has licensed master franchisees in the republics of Indonesia and Singapore, and the Philippines.
This press release contains information about Chemed's EBITDA, Adjusted EBITDA and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed's financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company's operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed's management similarly uses EBITDA, Adjusted EBITDA and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed's management to estimate the resources required to meet Chemed's future financial obligations and expenditures. Chemed's EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed's net income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release.
Forward-Looking Statements
Certain statements contained in this press release and the accompanying tables are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "hope," "anticipate," "plan" and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These statements are based on current expectations and assumptions and involve various risks and uncertainties, which could cause Chemed's actual results to differ from those expressed in such forward-looking statements.
These risks and uncertainties arise from, among other things, possible changes in regulations governing the hospice care or plumbing and drain cleaning industries; periodic changes in reimbursement levels and procedures under Medicare and Medicaid programs; difficulties predicting patient length of stay and estimating potential Medicare reimbursement obligations; challenges inherent in Chemed's growth strategy; the current shortage of qualified nurses, other healthcare professionals and licensed plumbing and drain cleaning technicians; Chemed's dependence on patient referral sources; and other factors detailed under the caption "Description of Business by Segment" or "Risk Factors" in Chemed's most recent report on form 10-Q or 10-K and its other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on such forward-looking statements and there are no assurances that the matters contained in such statements will be achieved.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)(unaudited)
Three Months Ended March 31,
2025 2024
Service revenues and sales $ 646,943 $ 589,233
Cost of services provided and goods sold 430,530 385,127
Selling, general and administrative expenses (aa) 105,587 115,873
Depreciation 13,445 13,287
Amortization 2,572 2,521
Other operating expense 51 92
Total costs and expenses 552,185 516,900
Income from operations 94,758 72,333
Interest expense (329) (425)
Other income--net (bb) 1,245 12,577
Income before income taxes 95,674 84,485
Income taxes (23,917) (19,468)
Net income $ 71,757 $ 65,017
Earnings Per Share
Net income $ 4.91 $ 4.30
Average number of shares outstanding 14,622 15,121
Diluted Earnings Per Share
Net income $ 4.86 $ 4.24
Average number of shares outstanding 14,764 15,339
(aa) Selling, general and administrative ("SG&A") expenses comprise (in thousands):
Three Months Ended March 31,
2025 2024
SG&A expenses before long-term incentive compensation
and the impact of market value adjustments related to
deferred compensation plans $ 103,760 $ 98,418
Long-term incentive compensation 2,657 9,121
Market value adjustments related to deferred
compensation trusts (830) 8,334
Total SG&A expenses $ 105,587 $ 115,873
(bb) Other income--net comprises (in thousands):
Three Months Ended March 31,
2025 2024
Interest income $ 2,076 $ 4,243
Market value adjustments related to deferred
compensation trusts (830) 8,334
Other (1) -
Total other income--net $ 1,245 $ 12,577
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)(unaudited)
March 31,
2025 2024
Assets
Current assets
Cash and cash equivalents $ 173,882 $ 313,350
Accounts receivable less allowances 285,873 177,334
Inventories 7,790 10,712
Prepaid income taxes 4,436 9,790
Prepaid expenses 30,404 28,431
Total current assets 502,385 539,617
Investments of deferred compensation plans held in trust 127,949 117,649
Properties and equipment, at cost less accumulated depreciation 199,679 202,784
Lease right of use asset 131,150 131,751
Identifiable intangible assets less accumulated amortization 89,929 88,137
Goodwill 666,940 591,519
Other assets 8,483 56,176
Total Assets $ 1,726,515 $ 1,727,633
Liabilities
Current liabilities
Accounts payable $ 47,692 $ 56,203
Accrued insurance 65,743 62,055
Accrued income taxes 38,247 27,353
Accrued compensation 59,905 49,802
Short-term lease liability 42,976 39,279
Other current liabilities 35,993 47,282
Total current liabilities 290,556 281,974
Deferred income taxes 11,771 24,899
Deferred compensation liabilities 127,292 117,550
Long-term lease liability 102,082 106,861
Other liabilities 13,052 12,854
Total Liabilities 544,753 544,138
Stockholders' Equity
Capital stock 37,535 37,297
Paid-in capital 1,538,419 1,398,733
Retained earnings 2,786,264 2,505,892
Treasury stock, at cost (3,182,718) (2,760,543)
Deferred compensation payable in Company stock 2,262 2,116
Total Stockholders' Equity 1,181,762 1,183,495
Total Liabilities and Stockholders' Equity $ 1,726,515 $ 1,727,633
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)(unaudited)
For the Three Months Ended March 31,
2025 2024
Cash Flows from Operating Activities
Net income $ 71,757 $ 65,017
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation and amortization 16,017 15,808
Stock option expense 9,091 9,025
Noncash long-term incentive compensation 2,420 9,106
Benefit for deferred income taxes (14,174) (5,422)
Amortization of debt issuance costs 80 80
Changes in operating assets and liabilities, excluding
amounts acquired in business combinations:
(Increase)/decrease in accounts receivable (67,424) 5,345
Decrease in inventories 403 1,302
(Increase)/decrease in prepaid expenses (4,430) 1,909
Decrease in accounts payable and
other current liabilities (22,592) (43,012)
Change in current income taxes 37,286 23,871
Net change in lease assets and liabilities 169 25
Decrease/(increase) in other assets 3,034 (12,243)
Increase in other liabilities 951 13,332
Other sources 156 406
Net cash provided by operating activities 32,744 84,549
Cash Flows from Investing Activities
Capital expenditures (13,280) (12,163)
Business combinations, net of cash acquired (225) (7,300)
Proceeds from sale of fixed assets 112 86
Other uses (281) (8)
Net cash used by investing activities (13,674) (19,385)
Cash Flows from Financing Activities
Purchases of treasury stock (33,222) (38,460)
Proceeds from exercise of stock options 22,666 37,242
Dividends paid (7,325) (6,050)
Capital stock surrendered to pay taxes on stock-based compensation (6,254) (5,725)
Change in cash overdrafts payable 438 (2,115)
Other sources/(uses) 159 (664)
Net cash used by financing activities (23,538) (15,772)
(Decrease)/Increase in Cash and Cash Equivalents (4,468) 49,392
Cash and cash equivalents at beginning of year 178,350 263,958
Cash and cash equivalents at end of period $ 173,882 $ 313,350
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024
(in thousands)(unaudited)
Chemed
VITAS Roto-Rooter Corporate Consolidated
2025 (a)
Service revenues and sales $ 407,400 $ 239,543 $ - $ 646,943
Cost of services provided and goods sold 312,807 117,723 - 430,530
Selling, general and administrative expenses 26,538 62,649 16,400 105,587
Depreciation 5,196 8,237 12 13,445
Amortization 26 2,546 - 2,572
Other operating expense/income 64 (13) - 51
Total costs and expenses 344,631 191,142 16,412 552,185
Income/(loss) from operations 62,769 48,401 (16,412) 94,758
Interest expense (48) (132) (149) (329)
Intercompany interest income/(expense) 5,296 3,930 (9,226) -
Other income net 48 10 1,187 1,245
Income/(loss) before income taxes 68,065 52,209 (24,600) 95,674
Income taxes (18,035) (12,265) 6,383 (23,917)
Net income/(loss) $ 50,030 $ 39,944 $ (18,217) $ 71,757
2024 (b)
Service revenues and sales $ 354,007 $ 235,226 $ - $ 589,233
Cost of services provided and goods sold 271,896 113,231 - 385,127
Selling, general and administrative expenses 23,792 61,260 30,821 115,873
Depreciation 5,166 8,108 13 13,287
Amortization 26 2,495 - 2,521
Other operating expense 7 85 - 92
Total costs and expenses 300,887 185,179 30,834 516,900
Income/(loss) from operations 53,120 50,047 (30,834) 72,333
Interest expense (46) (117) (262) (425)
Intercompany interest income/(expense) 5,194 3,442 (8,636) -
Other income net 29 22 12,526 12,577
Income/(loss) before income taxes 58,297 53,394 (27,206) 84,485
Income taxes (14,327) (12,541) 7,400 (19,468)
Net income/(loss) $ 43,970 $ 40,853 $ (19,806) $ 65,017
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARIES OF EBITDA
FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024
(in thousands)(unaudited)
Chemed
VITAS Roto-Rooter Corporate Consolidated
2025
Net income/(loss) $ 50,030 $ 39,944 $ (18,217) $ 71,757
Add/(deduct):
Interest expense 48 132 149 329
Income taxes 18,035 12,265 (6,383) 23,917
Depreciation 5,196 8,237 12 13,445
Amortization 26 2,546 - 2,572
EBITDA 73,335 63,124 (24,439) 112,020
Add/(deduct):
Intercompany interest expense/(income) (5,296) (3,930) 9,226 -
Interest income (49) (10) (2,017) (2,076)
Stock option expense - - 9,091 9,091
Long-term incentive compensation - - 2,657 2,657
Adjusted EBITDA $ 67,990 $ 59,184 $ (5,482) $ 121,692
2024
Net income/(loss) $ 43,970 $ 40,853 $ (19,806) $ 65,017
Add/(deduct):
Interest expense 46 117 262 425
Income taxes 14,327 12,541 (7,400) 19,468
Depreciation 5,166 8,108 13 13,287
Amortization 26 2,495 - 2,521
EBITDA 63,535 64,114 (26,931) 100,718
Add/(deduct):
Intercompany interest expense/(income) (5,194) (3,442) 8,636 -
Interest income (29) (22) (4,192) (4,243)
Stock option expense - - 9,026 9,026
Severance arrangement - - 5,337 5,337
Long-term incentive compensation - - 3,784 3,784
Adjusted EBITDA $ 58,312 $ 60,650 $ (4,340) $ 114,622
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
RECONCILIATION OF ADJUSTED NET INCOME
(in thousands, except per share data)(unaudited)
Three Months Ended March 31,
2025 2024
Net income as reported $ 71,757 $ 65,017
Add/(deduct) pre-tax cost of:
Stock option expense 9,091 9,026
Long-term incentive compensation 2,657 3,784
Amortization of reacquired franchise rights 2,352 2,352
Severance arrangement - 5,337
Add/(deduct) tax impacts:
Tax impact of the above pre-tax adjustments (1) (2,320) (2,388)
Excess tax benefits on stock compensation (463) (3,297)
Adjusted net income $ 83,074 $ 79,831
Diluted Earnings Per Share As Reported
Net income $ 4.86 $ 4.24
Average number of shares outstanding 14,764 15,339
Adjusted Diluted Earnings Per Share
Adjusted net income $ 5.63 $ 5.20
Average number of shares outstanding 14,764 15,339
(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
OPERATING STATISTICS FOR VITAS SEGMENT
(unaudited)
Three Months Ended March 31,
OPERATING STATISTICS 2025 2024
Net revenue ($000) (c)
Homecare $ 351,566 $ 304,860
Inpatient 34,022 30,303
Continuous care 24,637 24,169
Other 5,344 4,084
Subtotal $ 415,569 $ 363,416
Room and board, net (3,525) (2,944)
Contractual allowances (2,319) (4,090)
Medicare cap allowance (2,325) (2,375)
Net Revenue $ 407,400 $ 354,007
Net revenue as a percent of total before Medicare cap allowance
Homecare 84.6 % 83.9 %
Inpatient 8.2 8.3
Continuous care 5.9 6.7
Other 1.3 1.1
Subtotal 100.0 100.0
Room and board, net (0.8) (0.8)
Contractual allowances (0.6) (1.1)
Medicare cap allowance (0.6) (0.7)
Net Revenue 98.0 % 97.4 %
Days of care
Homecare 1,632,569 1,447,912
Nursing home 307,108 283,158
Respite 9,995 7,752
Subtotal routine homecare and respite 1,949,672 1,738,822
Inpatient 29,704 26,645
Continuous care 22,620 24,037
Total 2,001,996 1,789,504
Number of days in relevant time period 90 91
Average daily census ("ADC") (days)
Homecare 18,140 15,911
Nursing home 3,412 3,112
Respite 111 85
Subtotal routine homecare and respite 21,663 19,108
Inpatient 330 293
Continuous care 251 264
Total 22,244 19,665
Total Admissions 18,139 16,911
Total Discharges 17,875 16,170
Average length of stay (days) 118.7 103.9
Median length of stay (days) 16.0 16.0
ADC by major diagnosis
Cerebro 44.7 % 43.6 %
Neurological 12.4 13.4
Cancer 9.6 10.1
Cardio 16.1 16.1
Respiratory 7.2 7.2
Other 10.0 9.6
Total 100.0 % 100.0 %
Admissions by major diagnosis
Cerebro 28.4 % 27.7 %
Neurological 6.5 7.5
Cancer 24.6 24.6
Cardio 15.0 15.6
Respiratory 11.6 10.8
Other 13.9 13.8
Total 100.0 % 100.0 %
Estimated uncollectible accounts as a percent of revenues 0.6 % 1.1 %
Accounts receivable --
Days of revenue outstanding-excluding unapplied Medicare payments 47.3 42.3
Days of revenue outstanding-including unapplied Medicare payments 44.5 34.3
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
FOOTNOTES TO FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024
(unaudited)
(a) Included in the results of operations for 2025 are the following significant credits/(charges) which may not be indicative of ongoing operations
(in thousands):
Three Months Ended March 31, 2025
VITAS Roto-Rooter Corporate Consolidated
Stock option expense $ - $ - $ (9,091) $ (9,091)
Long-term incentive compensation - - (2,657) (2,657)
Amortization of reacquired franchise agreements - (2,352) - (2,352)
Pretax impact on earnings - (2,352) (11,748) (14,100)
Excess tax benefits on stock compensation - - 463 463
Income tax benefit on the above - 546 1,774 2,320
After-tax impact on earnings $ - $ (1,806) $ (9,511) $ (11,317)
(b) Included in the results of operations for 2024 are the following significant credits/(charges) which may not be indicative of ongoing operations
(in thousands):
Three Months Ended March 31, 2024
VITAS Roto-Rooter Corporate Consolidated
Stock option expense $ - $ - $ (9,026) $ (9,026)
Severence arrangement - - (5,337) (5,337)
Long-term incentive compensation - - (3,784) (3,784)
Amortization of reacquired franchise agreements - (2,352) - (2,352)
Pretax impact on earnings - (2,352) (18,147) (20,499)
Excess tax benefits on stock compensation - - 3,297 3,297
Income tax benefit on the above - 548 1,840 2,388
After-tax impact on earnings $ - $ (1,804) $ (13,010) $ (14,814)
(c) VITAS has 11 large (greater than 450 ADC), 23 medium (greater than 200 but less than 450 ADC) and 23 small (less than 200 ADC) hospice programs. Of Vitas' 34 Medicare provider numbers, for the trailing 12 months, 24 provider numbers have a Medicare cap cushion of greater than 10%, four provider numbers have a Medicare cap cushion between 0% and 10%, and six provider numbers have a Medicare cap liability.

Frequently Asked Questions

What were Chemed's Q1 2025 revenue results?

Chemed reported VITAS with net revenue of $407.4 million, a 15.1% increase.

How much did Covenant Health contribute to VITAS revenue?

Covenant Health contributed approximately $11.5 million to $12.5 million in revenue.

What was Roto-Rooter's revenue in Q1 2025?

Roto-Rooter generated quarterly revenue of $239.5 million, a 1.8% increase.

What is Chemed's cash position as of March 31, 2025?

Chemed had total cash and cash equivalents of $173.9 million.

When will Chemed update its 2025 earnings guidance?

Chemed plans to provide updated earnings guidance on June 30, 2025.

Last updated: Apr 23, 2025